Leukemia

The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat certain adults or children with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.

Patients with cancer have elevated risk for atrial fibrillation development, although the degree varies by cancer type, researchers reported in JACC: CardioOncology.

The FDA granted fast track designation to SNDX-5613 for the treatment of adults and children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia with certain genetic markers.

No methods or tests are available to detect susceptibility to acute lymphoblastic leukemia or lymphoblastic lymphomas. Likewise, there are no methodology or means to prevent these disorders.

Remission rates remained high with venetoclax and ibrutinib combination therapy after more than 3 years of follow-up among patients with previously untreated chronic lymphocytic leukemia, according to phase 2 study results in JAMA Oncology.

In this video, Richard M Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute discusses three studies; one that looked at an irreversible inhibitor of FLT3 in patients with relapsed refractory acute myeloid leukemia (AML), and two studies that looked at approaches to Philadelphia and Philadelphia-like acute lymphoblastic leukemia. Stone highlighted the importance of the study on Adult Philadelphia-like B-cell ALL. "This is an important study because, if it is corroborated prospectively, it means that we can identify Philadelphia-like patients fairly easily with a fairly narrow panel of FISH-identifiable lesions.”

In this video, Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute, spoke with Healio about a study presented at ASCO 2021 that showed high doses of aspacytarabine are safe to use in older patients with acute myeloid leukemia.

In this video Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana-Farber Institute, spoke with Healio about a study that showed a three-dose schedule of ponatinib with a higher initial dose was superior to other dosing methods for patients with chronic myeloid leukemia.

The FDA granted orphan drug designation to CTD401, a chimeric antigen receptor T-cell therapy for the treatment of T-cell acute lymphoblastic leukemia, according to the agent’s manufacturer.